Introduction
Fas is expressed on the surface of a variety of cell types, [1] [2] [3] thus making each of these cells susceptible to programmed death upon binding Fas-ligand (FasL). This mechanism can lead to fratricidal interaction among cells of the same type if they express both Fas and FasL, 4 or a controlled cell killing if one type of cell presents FasL and a different target cell presents Fas. [5] [6] [7] FasL is produced by activated T cells and NK cells, and triggers the apoptosis of Fas-positive target cells, including tumor cells. However, activated B and T lymphocytes also present Fas, and therefore can be deleted by other cells expressing FasL. 8, 9 A tumor immune privilege has been described as a function of the tumor cell's ability to produce a T lymphocyte deletion through the expression of FasL. [10] [11] [12] [13] Therefore, FasL expressing tumor cells can escape the immune surveillance, thus increasing the probability of the tumor progression. [10] [11] [12] [13] The protumor effect of the immune privilege created by FasL expression in cancer cells is demonstrated by the persistence of rapid growth and invasion, even in tumor cells that express both Fas and FasL. [14] [15] [16] The effect of intratumor T cell deletion represents a deprivation of antitumor effector and helper cell functions. This helper T cell deprivation can result in a deficient antitumor B cell immune reduce tumor progression, a plasmid encoding antisense FasL cDNA was delivered directly into a growing tumor (SW620 colon carcinoma). Intratumoral delivery of the plasmid was able to transfect tumor cells, stromal cells, and peritumoral muscle cells. This antisense FasL tumor tissue transfection persisted for at least 25 days, produced a systemic decrease in soluble FasL, and resulted in a 50% reduction in the rate of tumor growth when compared with tumor tissue of the control groups. These results suggest that direct transfection of antisense FasL cDNA impairs FasL translation in tumor and stromal cells, and can inhibit tumor progression by impairing the FasL-mediated, stromal cellassisted, tumor counter-attack. Gene Therapy (2001) 8, 209-214.
response. Additionally, FasL tumor cells are capable of directly depleting activated B cells. A B cell-deficient function may reduce the antigen targeted tumor cell destruction. FasL-expressing nontumor cells included in the tumor environment, such as macrophages and NK cells, can induce a local and random immune privilege through a FasL-mediated destruction of bystander lymphocytes, monocytes, and neutrophils. 17 All these data suggest that an induced suppression of FasL expression in the tumor environment could decrease or eliminate the tumor cell immune privilege, and result in increased effectiveness of the antitumor rejection process. In this paper, the feasibility of altering FasL expression through direct in situ, anti-sense FasL transfection, and the effects of FasL inhibition on tumor growth were tested. An athymic mouse model was used to evaluate the significance of the non-T cell mechanisms in natural tumor rejection.
Results
FasL-expressing tumor cells restrain the antitumor humoral immune response Given that tumor cells expressing FasL are able to suppress the cellular antitumor immune response, we designed an experiment to test whether the antitumor humoral response could also be deteriorated by that mechanism. A group of six isogeneic mice were injected with pcDNA3 transfected B16F10 cells (control group), a second group was injected with B16FL+ tumor cells (continuously expressing FasL under the control of the CMV promoter), a third with B16␤gal+ tumor cells (expressing ␤-gal, but not FasL), and a fourth group was injected with B16-FL/␤gal+ (expressing both ␤-gal and FasL). Three weeks after the tumor challenge, the test group injected with B16-FL tumor cells showed a 20% reduction in both spleen size and total splenocyte cell count compared with the controls. Flow cytometry analysis of the splenocytes confirmed a significant statistical reduction of both the total number of lymphocytes and the B cell/T cell ratio (Figure 1a ). In addition, the concentration of serum anti-␤-gal antibody was measured in the control group, the B16␤gal+ group, and the B16-FL/␤gal+ group. The level anti-␤-gal antibody present in the serum was significantly higher in animals carrying B16␤gal+ cells when compared with the level present in control animals (background). However, mice carrying B16-FL/␤gal+ cells had serum levels of anti-␤-gal antibody significantly lower than the mice carrying B16␤gal+ cells (Figure 1b) .
Direct, intratumoral injection of a plasmid induces transfection and expression of antisense FasL in tumor, and normal cells To determine the specific sites of expression that result from the direct injection of a plasmid into established tumors, the pcDNA/NT-GFP-FasL-9 mammalian expression vector encoding a green fluorescent protein (GFP) was injected into growing SW620 tumors in nu/nu mice. The transcription of this construct will initially yield a product that will contain the RNA sequences encoding both the GFP and antisense FasL in tandem. The appearance of a green fluorescence in the cytosol of transfected cells will be indicative of the presence of antisense FasL RNA. Three days after plasmid injection, the tumors and surrounding tissue were dissected. Frozen To determine whether the transcription of transfected antisense FasL by tumor cells, or by cells in the surrounding tissue, can alter tumor progression, an experiment was designed in which nu/nu mice were injected subcutaneously with SW620 tumor cells. When the tumors reached 5 mm in average diameter, the mice were divided into three separate groups. A control group received three intratumoral doses of PBS at 5-day increments. A second control group received three intratumoral doses of pcDNA 3.1 (plasmid not containing the anti-FasL sequence) at 5-day increments. Similarly, a test group received three intratumoral doses of the same plasmid encoding anti-sense FasL, also in 5-day increments. Tumor growth was monitored daily, and statistical analysis revealed a drastic reduction in the growth rate of tumors transfected with antisense FasL compared with that of the control group (Figure 3b) . Moreover, all untreated mice developed a tumor larger than 15 × 15 mm in less than 14 days. However, treated mice reached the same threshold between 35 and 60 days. 
Discussion
Immune surveillance avoidance by FasL-expressing tumor cells is extremely important to tumor growth. 9, 18 Regulation of the tumor's immune privilege could pro- duce a significant step forward in the creation of an antitumor therapy. Recently, the delivery of genes encoding growth factors and cytokines directly into the tumor environment have proven to be effective in antitumor treatments. 19 However, strategies to control tumor growth through the enhancement of the immune response against tumor have been generally disappointing. 20 One plausible explanation for this failure is that the tumor can counteract the T cell response through the creation of an environment of tumor immune privilege. Increasing the immune response against the tumor will fail as long as this immune privilege 10-13 remains intact. For this reason, active immune therapy alone will not overcome the anergy induced by the tumor.
In this experiment, mice injected with tumor cells expressing the reporter antigen ␤-gal showed an increase in serum antibodies against ␤-gal. This suggests that antigens expressed by tumor cells induce a humoral immune response. A similar experiment, in which mice were injected with tumor cells expressing both the reporter antigen and FasL, resulted in a statistical decrease in antibodies against the tumor when compared with animals injected with tumors expressing the reporter antigen alone. Although the amount of ␤-gal antigen produced by the tumor is difficult to assess quantitatively due to the nature of the chromogenic reaction, it is conceivable that the amount of ␤-gal produced by each tumor was similar and proportional to the tumor mass based on the fact that 100% of the ␤-gal stable transfected tumor cells (FasL co-transfected or non-FasL cotransfected) showed positive staining. Therefore, the reduction of anti-␤-gal Ab shown by the mice developing FasL transfected tumor cells indicates that the immune system was not able to effectively respond to the antigens produced by those tumor cells, and demonstrates the ability of FasLexpressing tumor cells to elude immune attack. The results suggest that an antitumor immune response was initiated, but this immune response was impaired in the presence of FasL expressing tumor cells. In an environment rich in FasL, tumor cells may induce immune cell activation, consequent expression of Fas by the activated cells, and subsequent FasL mediated killing of T-lymphocytes, 21 [10] [11] [12] [13] that fosters tumor progression. Targeting tumor tissue by vector delivery has proven to be more practical than injection of the vector of interest into peripheral blood. Direct injection avoids the need for a complicated targeting system capable of efficiently concentrating the vector(s) in the area of the tumor. 27 The primary goal of these experiments was to introduce a vector encoding antisense FasL into the tumor environment. Expression of the antisense FasL should: (a) block the expression of FasL within transfected tumor cells; and (b) negate the tumor's immune privilege. The first hypothesis was tested with an in vitro assay in which FasL expressing B16F10 cells were transfected with pcDNA/NT-GFP-FasL-9, and analyzed by flow cytometry. These experiments showed that most of the cells positive for FasL did not express GFP, and vice versa, suggesting that the antisense FasL expression was able to prevent the FasL translation.
However, the in vivo hypothesis contained several possible intrinsic flaws. (1) Direct in vivo nonviral vector delivery is normally aided by cationic liposomes. However, these reagents may induce artifacts that affect tumor growth. By not using these reagents, artifacts were avoided, but the risk of low transfection efficiency was increased. (2) Poor transfection efficiency could lead to a lack of response to the treatment. PCR amplification of the antisense FasL cDNA, and direct visualization of GFP expression, demonstrated that the sequence remained available in transfected tissues for at least 25 days beyond the initial injection. This period coincides with the average time that was necessary for tumor growth to reach the limit of the experiment (15 mm average tumor diameter). Therefore, expression of anti-sense FasL was possible throughout the entire duration of the experiment. The results obtained from the experiments using the reporter plasmid (pcDNA/NT-GFP-FasL-9) showed that only a minority (4.5% of the total cell count in the tumor tissue) of tumor cells actually expressed the transfected genes that were delivered in this manner. Many stromal cells (7.3% of the total cell count in the tumor tissue) also expressed the reporter gene, leading to the postulation that these cells (predominantly macrophages) were expressing the antisense FasL vector injected into tumors. Curiously, the most intense GFP fluorescence (reporter gene expression) was seen in muscle cells (in immediate contact with the limits of the tumor).
These results initially indicated a possible inefficiency in the proposed therapy. However, the animals carrying tumors which were injected with antisense FasL yielded an amount of soluble FasL in the serum which was approximately 45% less than that observed in animals injected with pcDNA 3.1 alone, demonstrating a change in the systemic turnover of this molecule. Although it is difficult to measure the amount of FasL and soluble-FasL in the tumor tissue, the significant systemic decrease of soluble FasL strengthens the possibility that a more effective FasL depletion could exist in the tumor environment.
Cells expressing FasL can delete lymphoid cells expressing Fas, achieving a privileged immunity. Moreover, this cellular protection can be provided by other bystander cells expressing FasL/soluble FasL. [9] [10] [11] [12] [13] For example, it has been demonstrated that introducing fibroblasts or myoblasts expressing FasL into the pancreatic structure results in the protection of transplanted islet cells through the creation of an immune privilege induced by the FasL transfected cells. 28, 29 It has been commonly misconceived that the immune privilege created in the tumor environment is solely dependent upon FasL expression by tumor cells. However, the data presented in this paper may suggest that stromal cells and other normal cells co-opted in the tumor mass (ie muscle cells) can contribute to the creation of an immune privileged tumor environment. This hypothesis is further supported by the reduction in the rate of tumor growth (approximately 50%), and the extended survival time of the test group (approximately 100%). Both were direct results of a treatment which transfected both tumor cells and stromal cells in the tumor environment.
The mechanism for this effect excludes the intervention of T cells due to the development of these experiments in a model using athymic mice. Therefore, FasL expressed in the environment of the tumor appears to be responsible for the depletion of B cells, NK cells, macrophages, and/or polymorphonuclear cells (all of which have been implicated in tumor cell rejection). In addition, it has been shown that the expression of the FasL molecule further aids tumor promotion through the enhancement of angiogenesis. 30 Thus, a blockade of FasL production could serve as a factor by which tumorpromoting angiogenesis is diminished, leading to a reduction in tumor growth. The results of our study illustrate that the direct transfection of antisense FasL cDNA through a nonviral vector into tumor tissue represents a valid experimental procedure for inhibiting cancer. Our results justify further investigation to determine if the procedures used in this particular mouse model have the potential to be translated into a therapeutic instrument for the clinical treatment of human cancer.
Materials and methods
Mice Four-to 6-week-old female, athymic nude (nu/nu) mice (Harlan Sprague Dawley, Indianapolis, IN, USA) were used for all experiments involving direct in vivo antisense delivery of the FasL molecule. Six-to 8-week-old female C57 BL/6 mice (Harlan Sprague Dawley) were used for all experiments involving ␤-gal and FasL in vitro transfections. Cells SW620, a human colon carcinoma cell line derived from lymph node metastasis, was obtained from American Type Culture Collection (Manassas, VA, USA). B16F10, a mouse melanoma cell line derived from C57 BL/6 mice, was kindly donated by Josh Fidler (University of Texas MD Anderson Cancer Center, Houston, TX, USA). All cells were maintained in DMEM supplemented with 10% fetal bovine serum, and incubated at 37°C in 5% CO 2 .
Tumor induction and monitoring
For all experiments, 10 6 cells (suspended in PBS) were injected subcutaneously. Tumor size was measured in two diameters at right angles using a caliper, and expressed in mm based on the average of those two tumor-diameter determinations.
Plasmid construction pZeoSV2/lacZ, pcDNA/NT-GFP-topo and pcDNA 3.1 vectors were purchased from Invitrogen (Carlsbad, CA, USA). pAVC3mFasL plasmid was kindly donated by S Nagata (Department of Molecular Biology, Osaka Bioscience Institute, Osaka, Japan). pcDNAFasL plasmids were constructed by ligation of the XbaI FasL fragment into the XbaI site of the pcDNA 3.1 vector. Ligation products were transformed into INV␣F′ competent E. coli (Invitrogen), and analyzed by restriction digestion to determine fragment orientation. Two clones were selected for large-scale plasmid preparation: pcDNAFasL+2 (sense FasL), and pcDNAFasL-9 (antisense FasL). pcDNA/NT-GFP-FasL-9 (antisense FasL) plasmid was constructed by PCR amplification of the pcDNAFasL-9 plasmid and ligation of the resulting fragment into the pcDNA/NT-GFP-topo vector. The pcDNA/NT-GFP-FasL-9 plasmid encodes a green fluorescent protein which allows for visual detection of transfected cells through UV microscopy. Clones were analyzed by restriction digestion to determine fragment orientation. All plasmids were prepared with the Plasmid Maxi Kit (Qiagen, Valencia, CA, USA).
In vitro transfections of B16F10 tumor cells with ␤-gal and FasL
In vitro transfections of 0.5-1 million, 30-50% confluent, B16F10 cells were carried out in six-well plates using the LipofectAMINE reagent (Gibco/Life Technologies, Baltimore, MD, USA). Three separate transfections were performed: pcDNA 3.1 alone, pZeoSV2/lacZ alone, and a cotransfection containing both pZeoSV2/lacZ and pcDNAFasL+2. Forty-eight hours after the completion of the transfections, 1 mg/ml of G418 supplemented medium was used to select for transfected cells. Stable clones expressing FasL were isolated by limited dilution, and verified by flow cytometry and RT-PCR. Stable clones expressing ␤-gal (B16␤gal+) were confirmed with the ␤-gal Staining Kit (Invitrogen).
Determination of ␤-gal expression in established, stably transfected B16F10 tumors B16F10␤gal+ tumors were dissected under sterile conditions. Tumor tissue fragments less than 1 cm 3 were explanted into Petri dishes, and supplemented with DMEM (20% FBS). After 5 days, tumor cells expanding from the periphery of the tumor tissue explants were stained for ␤-gal expression with the ␤-gal Staining Kit.
Determination of FasL protein expression B16F10 cells expressing FasL were immune stained with an antimouse FasL monoclonal antibody (PharMingen, San Diego, CA, USA) conjugated to phycoerythrin (PE). Flow cytometry analysis was performed with an EPICS Elite (Beckman Coulter, Miami, FL, USA).
Evaluation of B cell depletion in stably transfected B16F10 tumors Lymphocytes were obtained from the spleens of tumorbearing animals, and counted with a hemocytometer to estimate the total number of cells present. Identification of B cells was accomplished by B220 staining, and identification of T cells was accomplished by CD3 staining. B cell and T cell proportions were determined by flow cytometry.
Direct in vivo delivery of anti-sense FasL
In vivo transfections were performed through direct injection of 50 g (500 g/ml stock solution) of naked plasmid (suspended in PBS) into SW620 tumors established at 5 mm. The control groups received either PBS alone or the pcDNA 3.1 plasmid alone, and the test group received the pcDNAFasL-9 plasmid encoding antisense FasL. Each group (n = 5 mice) received three injections of the plasmid given at 5-day increments. After death, each tumor and its surrounding tissue were extracted, formalin-fixed, and embedded in paraffin blocks. Tumor cell DNA was obtained from 5 m sections through extensive proteinase K incubation followed by phenol/ chloroform/isoamyl alcohol extraction. Three PCR primers were designed to confirm the presence of the plasmid by amplification of the tumor-extracted DNA: (A) A common upstream primer located on the pcDNA 3.1 portion of the plasmid (5′-TAT CAT ATG CCA AGT ACG C-3′); (B) a downstream primer for amplifying anti-sense FasL (5′-CAA AGC CTT AAA GTA TCA TC-3′); and (C) a control downstream primer for amplifying sense FasL (5′-GTT AAA TGG GCC ACA CTC-3′). Positive and negative control amplifications verified that primers A and B amplified only the antisense FasL region (1052 bp), and primers A and C amplified only sense FasL (981 bp).
Anatomical distribution analysis of in vivo transfected cells Fifty g (500 g/ml stock solution) of pcDNA/NT-GFPFasL-9 plasmid was directly injected into 5 mm SW620 tumors established in athymic nu/nu mice. The animals were killed 30 days after injection. Tumors with a margin of surrounding tissue were surgically removed, immediately embedded in Tissue-Tek OCT compound (Sakura Finetek USA Inc., Torrance, CA, USA), stored at −20°C, and sectioned in a cryostat-microtome at −20°C. Fluorescence was examined with an Olympus (Melville, NY, USA) BX60 fluorescent microscope to observe the presence of green fluorescent protein. Parallel sections were stained with hematoxylin-eosin (H&E) to identify the cells by morphology.
Evaluation of anti-␤-gal antibody concentration in mouse sera
The mouse sera content of anti-␤-gal antibodies was tested by ELISA in 96-well plates coated with ␤-Gal (Invitrogen). Nonspecific binding was blocked with PBS, 0.05% Tween (Sigma, St Louis, MO, USA), 1% BSA (Sigma), and 2% goat serum (Sigma). Serum samples were diluted 1:50 in PBS with 0.05% Tween. The detection antibodies were horseradish-peroxidase (HRP)-conjugated goat-anti-mouse-IgM (Sigma), at a 1:5000 dilution. Anti-␤-gal IgM (Sigma) in a 1:2000 dilution was used in a similar fashion as a positive control. The chromagen TMB (3,3,5,5-tetramethylbenzidine, Gibco Life Technologies) was used to quantitate the antibody. Color intensity was measured at 450 nm.
Detection of soluble FasL in sera
The Fas ligand ELISA kit (Oncogene Research Products, Cambridge, MA, USA) was used to determine the concentration of soluble FasL present in the sera of athymic mice carrying SW620 tumors transfected with either pcDNAFasL-9, or pcDNA 3.1 .
Statistical analysis
Student's t test was used to compare the mean differences between samples.
